MedTrace Logo

Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65

NCT06917586 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-02-20

No results posted yet for this study

Summary

The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.

Conditions

  • Valve Disease, Heart
  • Valve Replacement
  • Valve Regurgitation, Mitral
  • Valve Heart Stenosis

Sponsors & Collaborators

  • Michael Moront

    lead OTHER

Principal Investigators

  • Michael Moront, MD · ProMedica Health System

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-07-01
Completion
2027-07-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06917586 on ClinicalTrials.gov